{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T07:20:10Z","timestamp":1795072810933,"version":"4.10.2"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,1,7]],"date-time":"2017-01-07T00:00:00Z","timestamp":1483747200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK2012854"],"award-info":[{"award-number":["BK2012854"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81173174"],"award-info":[{"award-number":["81173174"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21162009"],"award-info":[{"award-number":["21162009"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12885-016-3038-y","type":"journal-article","created":{"date-parts":[[2017,1,6]],"date-time":"2017-01-06T23:32:43Z","timestamp":1483745563000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Cryptotanshinone activates AMPK-TSC2 axis leading to inhibition of mTORC1 signaling in cancer cells"],"prefix":"10.1186","volume":"17","author":[{"given":"Wenxing","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siliang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenting","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,7]]},"reference":[{"key":"3038_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nrclinonc.2010.21","volume":"7","author":"J Dancey","year":"2010","unstructured":"Dancey J. mTOR signaling and drug development in cancer. Nat Rev Clin Oncol. 2010;7:209\u201319.","journal-title":"Nat Rev Clin Oncol"},{"key":"3038_CR2","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","volume":"149","author":"M Laplante","year":"2012","unstructured":"Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149:274\u201393.","journal-title":"Cell"},{"key":"3038_CR3","first-page":"eg4","volume":"5","author":"NR Gough","year":"2012","unstructured":"Gough NR. Focus issue: TOR signaling, a tale of two complexes. Sci Signal. 2012;5:eg4.","journal-title":"Sci Signal"},{"key":"3038_CR4","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S1097-2765(02)00636-6","volume":"10","author":"R Loewith","year":"2002","unstructured":"Loewith R, Jacinto E, Wullschleger S, Lorberg A, Crespo JL, Bonenfant D, Oppliger W, Jenoe P, Hall MN. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell. 2002;10:457\u201368.","journal-title":"Mol Cell"},{"key":"3038_CR5","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0092-8674(02)00833-4","volume":"110","author":"K Hara","year":"2002","unstructured":"Hara K, Maruki Y, Long X, Yoshino K, Oshiro N, Hidayat S, Tokunaga C, Avruch J, Yonezawa K. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell. 2002;110:177\u201389.","journal-title":"Cell"},{"key":"3038_CR6","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1126\/science.1106148","volume":"307","author":"DD Sarbassov","year":"2005","unstructured":"Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt\/PKB by the rictor-mTOR complex. Science. 2005;307:1098\u2013101.","journal-title":"Science"},{"key":"3038_CR7","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.cellsig.2009.01.004","volume":"21","author":"RM Memmott","year":"2009","unstructured":"Memmott RM, Dennis PA. Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Cell Signal. 2009;21:656\u201364.","journal-title":"Cell Signal"},{"key":"3038_CR8","doi-asserted-by":"publisher","first-page":"5856","DOI":"10.1158\/1078-0432.CCR-12-0662","volume":"18","author":"BM Slomovitz","year":"2012","unstructured":"Slomovitz BM, Coleman RL. The PI3K\/AKT\/mTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res. 2012;18:5856\u201364.","journal-title":"Clin Cancer Res"},{"key":"3038_CR9","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.pharmthera.2013.12.004","volume":"142","author":"J Polivka Jr","year":"2014","unstructured":"Polivka Jr J, Janku F. Molecular targets for cancer therapy in the PI3K\/AKT\/mTOR pathway. Pharmacol Therapeut. 2014;142:164\u201375.","journal-title":"Pharmacol Therapeut"},{"key":"3038_CR10","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1146\/annurev-pharmtox-010611-134537","volume":"52","author":"K Inoki","year":"2012","unstructured":"Inoki K, Kim J, Guan KL. AMPK and mTOR in cellular energy homeostasis and drug targets. Annu Rev Pharmacol. 2012;52:381\u2013400.","journal-title":"Annu Rev Pharmacol"},{"key":"3038_CR11","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nrm3311","volume":"13","author":"DG Hardie","year":"2012","unstructured":"Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Bio. 2012;13:251\u201362.","journal-title":"Nat Rev Mol Cell Bio"},{"issue":"12","key":"3038_CR12","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1177\/0091270005282630","volume":"45","author":"L Zhou","year":"2005","unstructured":"Zhou L, Zuo Z, Chow MS. Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol. 2005;45(12):1345\u201359.","journal-title":"J Clin Pharmacol"},{"key":"3038_CR13","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1002\/med.21304","volume":"34","author":"X Chen","year":"2014","unstructured":"Chen X, Guo J, Bao J, Lu J, Wang Y. The anticancer properties of Salvia miltiorrhiza Bunge (Danshen): a systematic review. Med Res Rev. 2014;34:768\u201394.","journal-title":"Med Res Rev"},{"key":"3038_CR14","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1158\/1940-6207.CAPR-10-0020","volume":"3","author":"W Chen","year":"2010","unstructured":"Chen W, Luo Y, Liu L, Zhou H, Xu B, Han X, Shen T, Liu Z, Lu Y, Huang S. Cryptotanshinone inhibits cancer cell proliferation by suppressing Mammalian target of rapamycin-mediated cyclin D1 expression and Rb phosphorylation. Cancer Prev Res (Phila). 2010;3:1015\u201325.","journal-title":"Cancer Prev Res (Phila)"},{"key":"3038_CR15","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1158\/0008-5472.CAN-08-2367","volume":"69","author":"CS Beevers","year":"2009","unstructured":"Beevers CS, Chen L, Liu L, Luo Y, Webster NJ, Huang S. Curcumin disrupts the Mammalian target of rapamycin-raptor complex. Cancer Res. 2009;69:1000\u20138.","journal-title":"Cancer Res"},{"key":"3038_CR16","doi-asserted-by":"publisher","first-page":"7029","DOI":"10.1038\/sj.onc.1209691","volume":"25","author":"L Liu","year":"2006","unstructured":"Liu L, Li F, Cardelli JA, Martin KA, Blenis J, Huang S. Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways. Oncogene. 2006;25:7029\u201340.","journal-title":"Oncogene"},{"key":"3038_CR17","first-page":"3504","volume":"60","author":"A Sekulic","year":"2000","unstructured":"Sekulic A, Hudson CC, Homme JL, Yin P, Otterness DM, Karnitz LM, Abraham RT. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res. 2000;60:3504\u201313.","journal-title":"Cancer Res"},{"key":"3038_CR18","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/labinvest.2010.36","volume":"90","author":"L Chen","year":"2010","unstructured":"Chen L, Xu B, Liu L, Luo Y, Yin J, Zhou H, Chen W, Shen T, Han X, Huang S. Hydrogen peroxide inhibits mTOR signaling by activation of AMPKalpha leading to apoptosis of neuronal cells. Lab Invest. 2010;90:762\u201373.","journal-title":"Lab Invest"},{"key":"3038_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","volume":"12","author":"DA Guertin","year":"2007","unstructured":"Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007;12:9\u201322.","journal-title":"Cancer Cell"},{"key":"3038_CR20","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.molcel.2008.03.003","volume":"30","author":"DM Gwinn","year":"2008","unstructured":"Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, Turk BE, Shaw RJ. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell. 2008;30:214\u201326.","journal-title":"Mol Cell"},{"key":"3038_CR21","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.tibs.2003.11.007","volume":"29","author":"Y Li","year":"2004","unstructured":"Li Y, Corradetti MN, Inoki K, Guan KL. TSC2: filling the GAP in the mTOR signaling pathway. Trends Biochem Sci. 2004;29:32\u20138.","journal-title":"Trends Biochem Sci"},{"key":"3038_CR22","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","volume":"124","author":"S Wullschleger","year":"2006","unstructured":"Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124:471\u201384.","journal-title":"Cell"},{"key":"3038_CR23","first-page":"295","volume":"3","author":"S Huang","year":"2002","unstructured":"Huang S, Houghton PJ. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr Opin Investig Drugs. 2002;3:295\u2013304.","journal-title":"Curr Opin Investig Drugs"},{"key":"3038_CR24","doi-asserted-by":"publisher","first-page":"6347","DOI":"10.1038\/sj.onc.1209885","volume":"25","author":"MN Corradetti","year":"2006","unstructured":"Corradetti MN, Guan KL. Upstream of the mammalian target of rapamycin: do all roads pass through mTOR? Oncogene. 2006;25:6347\u201360.","journal-title":"Oncogene"},{"key":"3038_CR25","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1002\/ijc.21932","volume":"119","author":"CS Beevers","year":"2006","unstructured":"Beevers CS, Li F, Liu L, Huang S. Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells. Int J Cancer. 2006;119:757\u201364.","journal-title":"Int J Cancer"},{"key":"3038_CR26","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.bbrc.2011.02.010","volume":"406","author":"GS Aller Van","year":"2011","unstructured":"Van Aller GS, Carson JD, Tang W, Peng H, Zhao L, Copeland RA, Tummino PJ, Luo L. Epigallocatechin gallate (EGCG), a major component of green tea, is a dual phosphoinositide-3-kinase\/mTOR inhibitor. Biochem Bioph Res Co. 2011;406:194\u20139.","journal-title":"Biochem Bioph Res Co"},{"key":"3038_CR27","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.2174\/18715206113139990113","volume":"13","author":"Y Wu","year":"2013","unstructured":"Wu Y, Liu F. Targeting mTOR: evaluating the therapeutic potential of resveratrol for cancer treatment. Anti-Cancer Agent Me. 2013;13:1032\u20138.","journal-title":"Anti-Cancer Agent Me"},{"key":"3038_CR28","doi-asserted-by":"publisher","first-page":"36387","DOI":"10.1074\/jbc.M110.169284","volume":"285","author":"M Liu","year":"2010","unstructured":"Liu M, Wilk SA, Wang A, Zhou L, Wang RH, Ogawa W, Deng C, Dong LQ, Liu F. Resveratrol inhibits mTOR signaling by promoting the interaction between mTOR and DEPTOR. J Biol Chem. 2010;285:36387\u201394.","journal-title":"J Biol Chem"},{"key":"3038_CR29","doi-asserted-by":"publisher","first-page":"971","DOI":"10.2174\/18715206113139990119","volume":"13","author":"X Tong","year":"2013","unstructured":"Tong X, Pelling JC. Targeting the PI3K\/Akt\/mTOR axis by apigenin for cancer prevention. Anti-Cancer Agent Me. 2013;13:971\u20138.","journal-title":"Anti-Cancer Agent Me"},{"key":"3038_CR30","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00418-011-0869-0","volume":"137","author":"AK Klappan","year":"2012","unstructured":"Klappan AK, Hones S, Mylonas I, Bruning A. Proteasome inhibition by quercetin triggers macroautophagy and blocks mTOR activity. Histochem Cell Biol. 2012;137:25\u201336.","journal-title":"Histochem Cell Biol"},{"key":"3038_CR31","doi-asserted-by":"publisher","first-page":"e47516","DOI":"10.1371\/journal.pone.0047516","volume":"7","author":"P Pratheeshkumar","year":"2012","unstructured":"Pratheeshkumar P, Budhraja A, Son YO, Wang X, Zhang Z, Ding S, Wang L, Hitron A, Lee JC, Xu M, et al. Quercetin inhibits angiogenesis mediated human prostate tumor growth by targeting VEGFR- 2 regulated AKT\/mTOR\/P70S6K signaling pathways. PLoS One. 2012;7:e47516.","journal-title":"PLoS One"},{"key":"3038_CR32","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.4161\/cc.10.13.16244","volume":"10","author":"AS Green","year":"2011","unstructured":"Green AS, Chapuis N, Lacombe C, Mayeux P, Bouscary D, Tamburini J. LKB1\/AMPK\/mTOR signaling pathway in hematological malignancies: from metabolism to cancer cell biology. Cell Cycle. 2011;10:2115\u201320.","journal-title":"Cell Cycle"},{"key":"3038_CR33","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1158\/0008-5472.CAN-12-3876","volume":"73","author":"J Liang","year":"2013","unstructured":"Liang J, Mills GB. AMPK: a contextual oncogene or tumor suppressor? Cancer Res. 2013;73:2929\u201335.","journal-title":"Cancer Res"},{"key":"3038_CR34","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.2337\/db13-0368","volume":"62","author":"DG Hardie","year":"2013","unstructured":"Hardie DG. AMPK: a target for drugs and natural products with effects on both diabetes and cancer. Diabetes. 2013;62:2164\u201372.","journal-title":"Diabetes"},{"key":"3038_CR35","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/j.1748-1716.2009.01967.x","volume":"196","author":"G Zhou","year":"2009","unstructured":"Zhou G, Sebhat IK, Zhang BB. AMPK activators--potential therapeutics for metabolic and other diseases. Acta Physiol (Oxf). 2009;196:175\u201390.","journal-title":"Acta Physiol (Oxf)"},{"key":"3038_CR36","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/onc.2012.181","volume":"32","author":"MA Pierotti","year":"2013","unstructured":"Pierotti MA, Berrino F, Gariboldi M, Melani C, Mogavero A, Negri T, Pasanisi P, Pilotti S. Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects. Oncogene. 2013;32:1475\u201387.","journal-title":"Oncogene"},{"key":"3038_CR37","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1749-6632.2011.06285.x","volume":"1243","author":"EJ Gallagher","year":"2011","unstructured":"Gallagher EJ, LeRoith D. Diabetes, cancer, and metformin: connections of metabolism and cell proliferation. Ann Ny Acad Sci. 2011;1243:54\u201368.","journal-title":"Ann Ny Acad Sci"},{"key":"3038_CR38","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1124\/mol.107.034447","volume":"72","author":"EJ Kim","year":"2007","unstructured":"Kim EJ, Jung SN, Son KH, Kim SR, Ha TY, Park MG, Jo IG, Park JG, Choe W, Kim SS, et al. Antidiabetes and antiobesity effect of cryptotanshinone via activation of AMP-activated protein kinase. Mol Pharmacol. 2007;72:62\u201372.","journal-title":"Mol Pharmacol"},{"key":"3038_CR39","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S0092-8674(03)00929-2","volume":"115","author":"K Inoki","year":"2003","unstructured":"Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell. 2003;115:577\u201390.","journal-title":"Cell"},{"key":"3038_CR40","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.cell.2006.06.055","volume":"126","author":"K Inoki","year":"2006","unstructured":"Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X, Yang Q, Bennett C, Harada Y, Stankunas K, et al. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell. 2006;126:955\u201368.","journal-title":"Cell"},{"key":"3038_CR41","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1158\/1940-6207.CAPR-11-0551","volume":"5","author":"W Chen","year":"2012","unstructured":"Chen W, Liu L, Luo Y, Odaka Y, Awate S, Zhou H, Shen T, Zheng S, Lu Y, Huang S. Cryptotanshinone activates p38\/JNK and inhibits Erk1\/2 leading to caspase-independent cell death in tumor cells. Cancer Prev Res (Phila). 2012;5:778\u201387.","journal-title":"Cancer Prev Res (Phila)"},{"key":"3038_CR42","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.freeradbiomed.2009.02.019","volume":"46","author":"BM Emerling","year":"2009","unstructured":"Emerling BM, Weinberg F, Snyder C, Burgess Z, Mutlu GM, Viollet B, Budinger GR, Chandel NS. Hypoxic activation of AMPK is dependent on mitochondrial ROS but independent of an increase in AMP\/ATP ratio. Free Radical Bio Med. 2009;46:1386\u201391.","journal-title":"Free Radical Bio Med"},{"key":"3038_CR43","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.1128\/MCB.05124-11","volume":"31","author":"PT Mungai","year":"2011","unstructured":"Mungai PT, Waypa GB, Jairaman A, Prakriya M, Dokic D, Ball MK, Schumacker PT. Hypoxia triggers AMPK activation through reactive oxygen species-mediated activation of calcium release-activated calcium channels. Mol Cell Biol. 2011;31:3531\u201345.","journal-title":"Mol Cell Biol."},{"key":"3038_CR44","doi-asserted-by":"publisher","first-page":"571","DOI":"10.2174\/187152010793498663","volume":"10","author":"H Zhou","year":"2010","unstructured":"Zhou H, Luo Y, Huang S. Updates of mTOR inhibitors. Anti-Cancer Agent Me. 2010;10:571\u201381.","journal-title":"Anti-Cancer Agent Me"},{"key":"3038_CR45","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1172\/JCI44145","volume":"121","author":"SA Wander","year":"2011","unstructured":"Wander SA, Hennessy BT, Slingerland JM. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest. 2011;121:1231\u201341.","journal-title":"J Clin Invest"},{"key":"3038_CR46","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1158\/1535-7163.MCT-10-0905","volume":"10","author":"E Vilar","year":"2011","unstructured":"Vilar E, Perez-Garcia J, Tabernero J. Pushing the envelope in the mTOR pathway: the second generation of inhibitors. Mol Cancer Ther. 2011;10:395\u2013403.","journal-title":"Mol Cancer Ther"},{"key":"3038_CR47","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1038\/onc.2010.630","volume":"30","author":"W Veelen van","year":"2011","unstructured":"van Veelen W, Korsse SE, van de Laar L, Peppelenbosch MP. The long and winding road to rational treatment of cancer associated with LKB1\/AMPK\/TSC\/mTORC1 signaling. Oncogene. 2011;30:2289\u2013303.","journal-title":"Oncogene"}],"updated-by":[{"DOI":"10.1186\/s12885-019-5458-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T00:00:00Z","timestamp":1553126400000}}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-3038-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-016-3038-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-3038-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T06:04:27Z","timestamp":1553234667000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-016-3038-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,7]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["3038"],"URL":"https:\/\/doi.org\/10.1186\/s12885-016-3038-y","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s12885-019-5458-y","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,7]]},"assertion":[{"value":"14 June 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2019","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Following publication of the original article [1], the author noticed the following errors in the article.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"34"}}